-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 6th, the official website of NMPA showed that the listing application (acceptance number: CYHS1900699) of the 4-type generic drug "Milaberon sustained-release tablets" by Hangzhou Huadong Pharmaceutical Group Zhejiang Huayi Pharmaceutical Co.
On April 6th, the official website of NMPA showed that the listing application (acceptance number: CYHS1900699) of the 4-type generic drug "Milaberon sustained-release tablets" by Hangzhou Huadong Pharmaceutical Group Zhejiang Huayi Pharmaceutical Co.
Mirabegron is the first approved β3 receptor agonist for overactive bladder (OAB), which selectively relaxes the bladder detrusor and promotes urine by acting on β-adrenergic receptors (β-ARs) Storage, thereby increasing the capacity of the bladder and extending the interval between urination, and does not affect the emptying of the bladder.
In 2020, during medical insurance negotiations, Astellas’s Mirabegron sustained-release tablets were reduced by 69.
Insight database shows that at present, only the original research of Mirabegron has been approved for marketing in China, and no generic drugs have been approved.
Source: Insight database (http://db.
Hangzhou Huadong Pharmaceutical Group Zhejiang Huayi Pharmaceutical Co.